TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia.
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs TK (Primary) ; T cell replacement therapy
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors MolMed
- 10 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Pooled results from this and other phase II study (profile 700030108) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 05 Dec 2016 Results published in the MolMed Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History